345 related articles for article (PubMed ID: 25552693)
1. The GSK-3 family as therapeutic target for myocardial diseases.
Lal H; Ahmad F; Woodgett J; Force T
Circ Res; 2015 Jan; 116(1):138-49. PubMed ID: 25552693
[TBL] [Abstract][Full Text] [Related]
2. Cardiac fibroblast glycogen synthase kinase-3β regulates ventricular remodeling and dysfunction in ischemic heart.
Lal H; Ahmad F; Zhou J; Yu JE; Vagnozzi RJ; Guo Y; Yu D; Tsai EJ; Woodgett J; Gao E; Force T
Circulation; 2014 Jul; 130(5):419-30. PubMed ID: 24899689
[TBL] [Abstract][Full Text] [Related]
3. GSK-3 at the heart of cardiometabolic diseases: Isoform-specific targeting is critical to therapeutic benefit.
Umbarkar P; Ruiz Ramirez SY; Toro Cora A; Tousif S; Lal H
Biochim Biophys Acta Mol Basis Dis; 2023 Aug; 1869(6):166724. PubMed ID: 37094727
[TBL] [Abstract][Full Text] [Related]
4. Cardiac fibroblast GSK-3α aggravates ischemic cardiac injury by promoting fibrosis, inflammation, and impairing angiogenesis.
Umbarkar P; Ejantkar S; Ruiz Ramirez SY; Toro Cora A; Zhang Q; Tousif S; Lal H
Basic Res Cardiol; 2023 Sep; 118(1):35. PubMed ID: 37656238
[TBL] [Abstract][Full Text] [Related]
5. Crosstalk between GSK-3β-actuated molecular cascades and myocardial physiology.
Sharma AK; Bhatia S; Al-Harrasi A; Nandave M; Hagar H
Heart Fail Rev; 2021 Nov; 26(6):1495-1504. PubMed ID: 32314086
[TBL] [Abstract][Full Text] [Related]
6. Fibroblast GSK-3α Promotes Fibrosis via RAF-MEK-ERK Pathway in the Injured Heart.
Umbarkar P; Tousif S; Singh AP; Anderson JC; Zhang Q; Tallquist MD; Woodgett J; Lal H
Circ Res; 2022 Sep; 131(7):620-636. PubMed ID: 36052698
[TBL] [Abstract][Full Text] [Related]
7. Glycogen synthase kinase-3beta regulates post-myocardial infarction remodeling and stress-induced cardiomyocyte proliferation in vivo.
Woulfe KC; Gao E; Lal H; Harris D; Fan Q; Vagnozzi R; DeCaul M; Shang X; Patel S; Woodgett JR; Force T; Zhou J
Circ Res; 2010 May; 106(10):1635-45. PubMed ID: 20360256
[TBL] [Abstract][Full Text] [Related]
8. Role of GSK-3 in Cardiac Health: Focusing on Cardiac Remodeling and Heart Failure.
Tariq U; Uppulapu SK; Banerjee SK
Curr Drug Targets; 2021; 22(13):1568-1576. PubMed ID: 33655828
[TBL] [Abstract][Full Text] [Related]
9. The mood stabilizing properties of AF3581, a novel potent GSK-3β inhibitor.
Capurro V; Lanfranco M; Summa M; Porceddu PF; Ciampoli M; Margaroli N; Durando L; Garrone B; Ombrato R; Tongiani S; Reggiani A
Biomed Pharmacother; 2020 Aug; 128():110249. PubMed ID: 32470749
[TBL] [Abstract][Full Text] [Related]
10. Drug development targeting the glycogen synthase kinase-3beta (GSK-3beta)-mediated signal transduction pathway: role of GSK-3beta in myocardial protection against ischemia/reperfusion injury.
Miura T; Nishihara M; Miki T
J Pharmacol Sci; 2009 Feb; 109(2):162-7. PubMed ID: 19179805
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of glycogen synthase kinase 3beta during heart failure is protective.
Hirotani S; Zhai P; Tomita H; Galeotti J; Marquez JP; Gao S; Hong C; Yatani A; Avila J; Sadoshima J
Circ Res; 2007 Nov; 101(11):1164-74. PubMed ID: 17901358
[TBL] [Abstract][Full Text] [Related]
12. Glycogen synthase kinase-3 beta (GSK-3β) signaling: Implications for Parkinson's disease.
Golpich M; Amini E; Hemmati F; Ibrahim NM; Rahmani B; Mohamed Z; Raymond AA; Dargahi L; Ghasemi R; Ahmadiani A
Pharmacol Res; 2015 Jul; 97():16-26. PubMed ID: 25829335
[TBL] [Abstract][Full Text] [Related]
13. Targeting GSK-3 family members in the heart: a very sharp double-edged sword.
Cheng H; Woodgett J; Maamari M; Force T
J Mol Cell Cardiol; 2011 Oct; 51(4):607-13. PubMed ID: 21163265
[TBL] [Abstract][Full Text] [Related]
14. Glycogen synthase kinase-3alpha reduces cardiac growth and pressure overload-induced cardiac hypertrophy by inhibition of extracellular signal-regulated kinases.
Zhai P; Gao S; Holle E; Yu X; Yatani A; Wagner T; Sadoshima J
J Biol Chem; 2007 Nov; 282(45):33181-91. PubMed ID: 17855351
[TBL] [Abstract][Full Text] [Related]
15. The signaling interplay of GSK-3β in myocardial disorders.
Sharma AK; Thanikachalam PV; Bhatia S
Drug Discov Today; 2020 Apr; 25(4):633-641. PubMed ID: 32014454
[TBL] [Abstract][Full Text] [Related]
16. PARP inhibition prevents postinfarction myocardial remodeling and heart failure via the protein kinase C/glycogen synthase kinase-3beta pathway.
Palfi A; Toth A; Hanto K; Deres P; Szabados E; Szereday Z; Kulcsar G; Kalai T; Hideg K; Gallyas F; Sumegi B; Toth K; Halmosi R
J Mol Cell Cardiol; 2006 Jul; 41(1):149-59. PubMed ID: 16716347
[TBL] [Abstract][Full Text] [Related]
17. Entanglement of GSK-3β, β-catenin and TGF-β1 signaling network to regulate myocardial fibrosis.
Guo Y; Gupte M; Umbarkar P; Singh AP; Sui JY; Force T; Lal H
J Mol Cell Cardiol; 2017 Sep; 110():109-120. PubMed ID: 28756206
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of GSK-3beta as a target for cardioprotection: the importance of timing, location, duration and degree of inhibition.
Murphy E; Steenbergen C
Expert Opin Ther Targets; 2005 Jun; 9(3):447-56. PubMed ID: 15948666
[TBL] [Abstract][Full Text] [Related]
19. Constitutive glycogen synthase kinase-3alpha/beta activity protects against chronic beta-adrenergic remodelling of the heart.
Webb IG; Nishino Y; Clark JE; Murdoch C; Walker SJ; Makowski MR; Botnar RM; Redwood SR; Shah AM; Marber MS
Cardiovasc Res; 2010 Aug; 87(3):494-503. PubMed ID: 20299330
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of glycogen synthase kinase 3β induces dermal fibrosis by activation of the canonical Wnt pathway.
Bergmann C; Akhmetshina A; Dees C; Palumbo K; Zerr P; Beyer C; Zwerina J; Distler O; Schett G; Distler JH
Ann Rheum Dis; 2011 Dec; 70(12):2191-8. PubMed ID: 21873331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
